1. がん情報サービス 国立がん研究センター ganjoho.jp
2. Sorenmo KU, Worley DR, Goldschimidt MH. Tumors of the mammary gland. In: Withrow & MacEwens Small animal Clinical Oncology, (withrow SJ, Vali DM, Page RL. Eds), 5th ed. 2013; 538-56.
3. 日本乳癌学会 乳癌診療ガイドライン http://jbcs.gr.jp/guidline/
4. Goldhirsch A, Winter EP, Coates AS, et al. : Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Cancer. Ann Oncol. 2013;24:2206- 23.
5. 公益財団法人がん研究振興財団.がんの統計’16. http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2016_jp.html.
6. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long‒term follow‒up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197‒205.
7. Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow‒up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‒containing chemotherapy:a reference. Cancer. 1999;85(1):104‒ 11.
8. Abadie J, Nguyen F, Loussouarn D, et al. Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast Cancer Res Treat. 2018;167:459-468.
9. Soares M, Correia J, Peleteiro M.C, et al. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053–4064.
10. Papavramidou N, Paparamidis T, Demetriou T. Ancient greek and Greco-roman methods in modern surgical treatment of cancer. Ann Surg Oncol. 2010;17:665- 7.
11. Willis RA. The spread of tumours in the human body. Butterworth and Co. 1952.
12. Bussard KM, Mutkus L, Stumpf K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016; 18;84.
13. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-37.
14. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol. 2013;13:227-42.
15. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30.
16. Mordenti J, Thomsen K, Licko V, et al. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol. 1999;27:14-21.
17. Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med. 2017;19:148-53.
18. de Groot AF, Appelman-Dijkstra NM, van der Burg SH, et al. The anti-tumor effect of RANKL inhibition in malignant solid tumors- A systematic reviews. Cancer Treat Rev. 2018;62:18-28.
19. Kato D, Yaguchi T, Iwata T, et al. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40:68-77.
20. Karamouzis MV, Moschos SJ. The use of endostatin in the treatment of solid tumors. Expert Opin Biol Ther. 2009;9:641-8.
21. Yamada KM, Yamada SS, Pastan I. The major cell surface glycoprotein of chick embryo fibroblasts is an agglutinin. Proc Natl Acad Sci U S A. 1975; 72:3158-62.
22. Grumet M, Hoffman S, Crossin KL, et al. Cytotactin, an extracellular matrix protein of neural and non-neural tissues that mediates glia-neuron. Proc Natl Acad Sci USA. 1985 Dsc;82:8075-9.
23. Kruse J, Keilhauer G, Faissner A, et al. The J1 glycoprotein--a novel nervous system cell adhesion molecule of the L2/HNK-1 family. Nature. 1985 Jul 11- 17;316:146-8.
24. Erickson HP, Inglesias JL. A six-armed oligomer isolated from cell surface fibronectin preparations. Nature. 1984 Sep 20-26;311:267-9.
25. Chiquet M, Fambrough DM. Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis. J Cell Biol. 1984 Jun;98:1926-36.
26. Chiquet M, Fambrough DM. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol. 1984 Jun;98:1937-46.
27. Bourdon MA, Wikstrand CJ, Furthmayr H, et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983 Jun;43:2796-805.
28. Chiquet-Ehrismann R, Mackie EJ, Person CA, et al. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell. 1986; 47:131-9.
29. Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol. 2011;3.
30. Giblin S, Midwood KS. Tenascin-C: form versus function. Cell Adh Migr. 2015;9:48-82.
31. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal, 2009;3:287-310.
32. Aufderheide E, Chiquet-Ehrismann R, Ekblom P. Epithelial-mesenchymal interactions in the developing kidney lead to expression of tenascin in the mesenchyme. J Cell Biol. 1987;105:599-608.
33. Natali PG, Nicotra MR, Bigotti A, et al. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer. 1991; 47:811-6.
34. Erickson HP, Bourdon MA. Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71-92.
35. Sakakura T. Role of tenascin in cancer development. In Tumor Matrix Biology, (ed. Adany R.) CRC Press. 1995:101-29.
36. Midwood KS, Hussenet T, Langlois B, et al. Advances in tenascin-C biology. Cell Mol Life Sci. 2001;68:3175-99.
37. 坂倉照妤, 日下部守昭. 炎症におけるテネイシン発現の多様な調節機構. 炎症. 1995;15:377-81.
38. Murakami R, Yamaoka I, Sakakura T. Appearance of tenascin in healing skin of the wounded tissues. Int J Dev Biol. 1989;33:439-44.
39. Mackie E, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol. 1988;107:2757-67.
40. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143-63.
41. Yang Z, Ni W, Fang L, et al. Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma. Exp Mol Pathol. 2017;102:262-7.
42. Jahkola T, Toivonen T, von Smitten K, et al. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer. 1996;69:445-7.
43. Tokes AM, Szasz AM, Farkas A, et al. Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res. 2009;15:731-9.
44. Yoshimura H, Michishita M, Ohkusu-Tsukada K, et al. Cellular sources of tenascin-C in canine mammary carcinomas. Vet Pathol. 2015;52:92-6.
45. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci U S A. 1987;84:4621-5.
46. Brellier F, Chiquet-Ehrismann R. How do tenascins influence the birth and life of a malignant cell? J Cell Mol Med. 2012;16:32-40.
47. Saupe F, Schwenzer A, Jia Y, et al. Tenascin-C Downregulates Wnt Inhibitor Dickkopf-1, Promoting Tumorigenesis in a Neuroendocrine Tumor Model. Cell Rep. 2013;5: 482-492.
48. Talts JF, Wirl G, Dictor M, et al. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci. 1999;112:1855-1864.
49. Chiovaro F, Chiquet-Ehrismann R, Chiquet M. Transcriptional regulation of tenascin genes. Cell Adh Migr. 2015;9:34-47.
50. Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res. 1989;49:4322-5.
51. Hiraiwa N, Kida H, Sakakura T, et al. Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor. J Cell Sci. 1993;104:289-96.
52. Calvo A, Catena R, Noble MS, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27:5373-84.
53. Tanaka K, Hiraiwa N, Hashimoto H, et al. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. 2004;108:31-40.
54. Hirata E, Arakawa Y, Shirahata M, et al. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 2009;100:1451-9.
55. O’Connell JT, Sugimoto H, Cooke VG, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011;108:16002-7.
56. Oskarsson T, Acharyya S, Zhang XH,et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17: 867 74.
57. Tsunoda T, Inada H, Kalemeyi I, et al. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol. 2003; 162(6):1857-67.
58. Atula T, Hedstrom J, Finne P, et al. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. Anticancer Res. 2003;23:3051-6.
59. Aishima S, Taguchi K, Terashi T, et al. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol. 2003;16:1019-27.
60. Iskaros BF, Koss LG. Tenascin expression in intraepithelial neoplasia and invasive carcinoma of the uterine cervix. Arch Pathol Lab Med. 2000;124:1282- 6.
61. Ishihara A, Yoshida T, Tamaki H, et al. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res. 1995;1:1035-41.
62. Hanamura N, Yoshida T, Matsumoto E, et al. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer. 1997;73:10-5.
63. Kalembey I, Yoshida T, Iriyama K, et al. Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: an in situ hybridization study. Int J Dev Biol. 1997;41:569-73.
64. Sakai T, Kawakatsu H, Ohta M, et al. Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF-beta1 in vitro. J Cell Physiol. 1994;159:561-72.
65. Inaguma Y, Kusakabe M, Mackie EJ, et al. Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis. Dev Biol. 1988;128:245-55.
66. Proskuryakov SY, Gabai VL. Mechanisms of tumor cell necrosis. Curr Pharm Des. 2010;16:56-68.
67. R Development Core Team. R: A language and environment for statistical computing. 2005.
68. Gautier L, Cope L, Bolstad BM, et al. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307-15.
69. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics. 2010;11:242-53.
70. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23:1846-7.
71. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207-10.
72. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27-30.
73. Kutmon M, Riutta A, Nunes N, et al. WikiPathways: capturing the full diversity of pathway knowledge. Nucleic Acids Res. 2015;gkv1024.
74. Milacic M, Haw R, Rothfels K, et al. Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers. 2012;4:1180-1211.
75. Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinforma. 2011;27:431-2.
76. Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091-3.
77. Warnes GR, Bolker B, Bonebakker L, et al. gplots: Various R Programming Tools for Plotting Data. 2015.
78. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-50.
79. Zhu Q, Han X, Peng J, et al. The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol. 2012;43:699-713.
80. Strieter RM, Polverini PJ, Kunkel SL, et al. The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis. J Biol Chem. 1995;270:27348- 57.
81. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 2011;317:685-90.
82. Keane MP, Belperio JA, Xue YY, et al. Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer. J Immunol. 2004;172:2853-60.
83. Lowy CM, Oskarsson T. Tenascin C in metastasis: A view from the invasive front. Cell Adhes Migr. 2015;9:112-24.
84. Strieter RM, Belperio JA, Burdick MD, et al. CXC Chemokines: Angiogenesis, Immunoangiostasis, and Metastases in Lung Cancer. Ann N Y Acad Sci. 2004;1028:351-60.
85. Pan J, Burdick MD, Belperio JA, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol. 2006;176: 1456-64.
86. 特許第 3850492 号『テネイシン誘導因子』日下部守昭
87. Beiter K, Hiendlmeyer E, Braletz T, et al. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 2005;24:8200-4.
88. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol. 2000;19:581-96.
89. Imai K, Kusakabe M, Sakakura T, et al. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett. 1994;352:216- 8.
90. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 1994;54:439-53.
91. Siri A, Knauper V, Veirana N, et al. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J boil Chem. 1995;270:8650-4.
92. Jinnin M, Ihn H, Asano Y, et al. Platelet derived growth factor induced tenascinC transcription is phosphoinositide 3-kinase/Akt-dependent and mediated by Ets family transcription factors. J Cell Physiol. 2006;206:718-27.
93. Chiquet M, Sarasa-Renedo A, Tunc-Civelek V. Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta. 2004;1693:193-204.
94. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;518:382-7.
95. Susanne S, Jurgen M, Gunter V, et al. Tenascin-C in serum: a questionable tumor marker. Int J Cancer. 1995;61:443-9.
96. Popova OP, Bogomazova SY, Ivanov AA. Role of tenascin C in triple-negative breast cancer. Arkh pathol. 2017;79:10-15.